Why Redhill Biopharma Stock Is Moving Higher

Redhill Biopharma Ltd. shares are trading higher Wednesday after the company was granted a patent for a method for eradicating helicobacter pylori infections in patients regardless of body mass index.

Redhill Biopharma Ltd. (NASDAQ:RDHL) shares are trading higher Wednesday after the company was granted a patent for a method for eradicating helicobacter pylori infections in patients regardless of body mass index.

The Details:

Redhill Biopharma shares are moving on above-average trading volume Wednesday. According to data from Benzinga Pro, more than 7.27 million shares have already been traded in the session, compared to the stock’s 100-day average of 9.125 million shares.

In late December, RedHill Biopharma announced that two of its investigational drugs, opaganib and RHB-107 (upamostat), demonstrated robust synergistic effect when combined individually with remdesivir (Veklury), in a U.S. Army-funded and conducted Ebola virus in vitro study.

“Opaganib and RHB-107 are both novel, oral, host-directed, small molecule investigational drugs with demonstrated activity against multiple viral targets, including COVID-19, and are expected to be effective against emerging viral variants. This, together with their growing safety and tolerability databases, presents a compelling hypothesis for further study of their potential in treating Ebola virus,” said Reza Fathi, Ph.D., senior vice president of research and development at RedHill.

Related News: What’s Going On With Spirit Airlines Stock?

RDHL Price Action: According to Benzinga Pro, RedHill Biopharma shares are up 22% at $1.09 at the time of publication.

Image: Emilian Danaila from Pixabay

Total
0
Shares
Related Posts
Read More

This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023, Trims Losses

Cannabinoids-focused pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Wednesday its financial results for the full year and three months ended Dec. 31, 2023. Net revenue grew to CA$33 million ($24.3 million), from CA$22.1 million in 2022, representing roughly a 50% year-over-year increase. "Over the years we have invested in our infrastructure as a high quality and high-capacity pharmaceutical grade manufacturer, allowing us to grow sales with new opportunities and markets, without additional investment into capital or resources," David Pidduck said. "We are proud of the work completed in 2023 and excited about the future of MediPharm Labs."

MEDIF